Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Denys

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Neurourology and Urodynamics|October 8, 2010
Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retentionEmmanuel Chartier-Kastler, Pierre Denys
La Revue Du Praticien|November 2, 2011
[Conservative treatment of female urinary incontinence]Jacques Kerdraon, Pierre Denys, Gérard Amarenco
Toxins|May 24, 2019
Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport<sup>®</sup>) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction-Case StudiesFrancois Giuliano, Charles Joussain, Pierre Denys
Toxins|April 21, 2022
Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin<sup>®</sup>) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case SeriesFrancois Giuliano, Pierre Denys, Charles Joussain
The Journal of Sexual Medicine|December 23, 2021
Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile DysfunctionFrancois Giuliano, Charles Joussain, Pierre Denys
Annals of Physical and Rehabilitation Medicine|June 18, 2017
What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world?Mikolaj Przydacz, Pierre Denys, Jacques Corcos
Toxins|June 27, 2023
Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational DataFrançois Giuliano, Pierre Denys, Charles Joussain
Autonomic Neuroscience : Basic & Clinical|July 10, 2026
Treating neurogenic detrusor overactivity in order to manage autonomic dysreflexia - A systematic reviewBa Thien Le, Pierre Denys, Charles Joussain
Toxins|October 25, 2024
Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from FranceAlain Ruffion, Pierre Karam, Anne Forestier, et al.
Current Opinion in Urology|November 25, 2010
Botulinum neurotoxin A for male lower urinary tract symptomsEmmanuel Chartier-Kastler, Ulrich Mehnert, Pierre Denys, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Neurourology and Urodynamics|October 8, 2010
Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retentionEmmanuel Chartier-Kastler, Pierre Denys
La Revue Du Praticien|November 2, 2011
[Conservative treatment of female urinary incontinence]Jacques Kerdraon, Pierre Denys, Gérard Amarenco
Toxins|May 24, 2019
Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport<sup>®</sup>) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction-Case StudiesFrancois Giuliano, Charles Joussain, Pierre Denys
Toxins|April 21, 2022
Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin<sup>®</sup>) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case SeriesFrancois Giuliano, Pierre Denys, Charles Joussain
The Journal of Sexual Medicine|December 23, 2021
Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile DysfunctionFrancois Giuliano, Charles Joussain, Pierre Denys
Annals of Physical and Rehabilitation Medicine|June 18, 2017
What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world?Mikolaj Przydacz, Pierre Denys, Jacques Corcos
Toxins|June 27, 2023
Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational DataFrançois Giuliano, Pierre Denys, Charles Joussain
Autonomic Neuroscience : Basic & Clinical|July 10, 2026
Treating neurogenic detrusor overactivity in order to manage autonomic dysreflexia - A systematic reviewBa Thien Le, Pierre Denys, Charles Joussain
Toxins|October 25, 2024
Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from FranceAlain Ruffion, Pierre Karam, Anne Forestier, et al.
Current Opinion in Urology|November 25, 2010
Botulinum neurotoxin A for male lower urinary tract symptomsEmmanuel Chartier-Kastler, Ulrich Mehnert, Pierre Denys, et al.
Pageof 12